Basic Stats
| LEI | 549300TGHXVKQ7EJRO41 |
| CIK | 1582554 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Matinas BioPharma Holdings, Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (C |
|
| August 18, 2025 |
MATINAS BIOPHARMA HOLDINGS, INC. WARRANT EXCHANGE AGREEMENT Exhibit 10.1 MATINAS BIOPHARMA HOLDINGS, INC. WARRANT EXCHANGE AGREEMENT This Warrant Exchange Agreement (this “Agreement”) is made as of August 15, 2025 (“Effective Date”), by and between Matinas Biopharma Holdings, Inc., a Delaware corporation (the “Company”), and the holder signatory hereto (the “Holder”). RECITALS WHEREAS, the Holder currently holds warrants (the “Warrants”) to purchase shares |
|
| August 14, 2025 |
Form of Amendment to Common Stock Purchase Warrant* Exhibit 4.4 OMNIBUS WARRANT AMENDMENT This OMNIBUS WARRANT AMENDMENT (this “Amendment”) is dated as of June 26, 2025 (the “Effective Date”) by and among Matinas Biopharma Holdings, Inc., a Delaware corporation (the “Company”), and the warrant holders signatory hereto (each a “Warrant Holder” and collectively, the “Warrant Holders”). Capitalized terms used herein and not otherwise defined shall hav |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOL |
|
| August 6, 2025 |
Exhibit 10.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF MATINAS BIOPHARMA HOLDINGS, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware, Matinas BioPharma Holdings, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: 1. The name of the Corporation is Matinas BioPhar |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (Co |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (Com |
|
| June 23, 2025 |
As filed with the Securities and Exchange Commission on June 23, 2025 As filed with the Securities and Exchange Commission on June 23, 2025 Registration No. |
|
| June 23, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Matinas BioPharma Holdings, Inc. |
|
| June 23, 2025 |
Matinas BioPharma Holdings, Inc. 2025 Equity Incentive Plan Exhibit 10.1 MATINAS BIOPHARMA HOLDINGS, INC. 2025 Equity INCENTIVE Plan 1. Establishment and Purpose 1.1 The purpose of the Matinas BioPharma Holdings, Inc. 2025 Equity Incentive Plan (the “Plan”) is to provide a means whereby eligible employees, officers, non-employee directors and other individual service providers develop a sense of proprietorship and personal involvement in the development an |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HO |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| May 2, 2025 |
Amendment No. 1 to the Bylaws of the Company Exhibit 3.1 AMENDMENT NO.1 TO THE BYLAWS OF MATINAS BIOPHARMA HOLDINGS, INC. This Amendment No. 1 to the Bylaws (the “Bylaws”) of Matinas Biopharma Holdings, Inc., a Delaware corporation (the “Company”) is made as of this day of , 2025. 1. The Bylaws are hereby amended by replacing the first sentence of Section 5 of the Bylaws with the following: “One-third of the voting power of the shares entitl |
|
| May 2, 2025 |
Exhibit 10.1 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment (“Amendment”), dated as of April 30, 2025 (the “Amendment Date”), amends the Employment Agreement between MATINAS BIOPHARMA HOLDINGS, INC. (the “Company”) and JEROME JABBOUR (the “Executive”) dated March 22, 2018, as amended by that certain amendment dated as of March 3, 2023 (the “Agreement”). All capitalized terms not de |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (Co |
|
| May 2, 2025 |
Exhibit 10.2 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment (“Amendment”), dated as of April 30, 2025 (the “Amendment Date”), amends the Employment Agreement between MATINAS BIOPHARMA HOLDINGS, INC. (the “Company”) and KEITH A. KUCINSKI, CPA (the “Executive”) dated December 31, 2018 and commencing as of January 2, 2019, as amended by that certain amendment dated as of March 3, 2023 |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 29, 2025 |
16,894,212 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-286686 PROSPECTUS 16,894,212 Shares of Common Stock This prospectus relates to the resale of up to 16,894,212 shares of common stock, par value $0.0001 per share (“Common Stock”), of Matinas Biopharma Holdings, Inc. (the “Company,” “we,” “our” or “us”) by the Selling Stockholders listed in this prospectus (the “Selling Stockholders”). The share |
|
| April 28, 2025 |
Matinas BioPharma Holdings, Inc. 1545 Route 206 South, Suite 302 Bedminster, New Jersey 07921 Matinas BioPharma Holdings, Inc. 1545 Route 206 South, Suite 302 Bedminster, New Jersey 07921 April 28, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Matinas BioPharma Holdings, Inc. Registration Statement on Form S-3 (File No. 333-286686) Filed on April 22, 2025 Ladies and Gentlemen: In accordance with |
|
| April 22, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) MATINAS BIOPHARMA HOLDINGS, INC. |
|
| April 22, 2025 |
As filed with the Securities and Exchange Commission on April 22, 2025 As filed with the Securities and Exchange Commission on April 22, 2025 Registration No. |
|
| April 15, 2025 |
Matinas BioPharma Holdings, Inc. Compensation Recovery Policy* Exhibit 97.1 MATINAS BIOPHARMA HOLDINGS, INC. COMPENSATION RECOVERY POLICY (Adopted and approved on November 30, 2023) 1. Purpose Matinas BioPharma Holdings, Inc. (collectively with its subsidiaries, the “Company”) is committed to promoting high standards of honest and ethical business conduct and compliance with applicable laws, rules and regulations. As part of this commitment, the Company has a |
|
| April 15, 2025 |
Exhibit 21.1 Subsidiaries of Matinas BioPharma Holdings, Inc. Name State of Incorporation Matinas BioPharma, Inc. Delaware Matinas BioPharma Nanotechnologies, Inc. Delaware |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS |
|
| April 15, 2025 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of our common stock, preferred stock and warrants, as set forth in our certificate of incorporation, the Certificate of Designation of the Series C Convertible Preferred Stock, the Form of Warrant and our bylaws, each of which is incorporate |
|
| April 8, 2025 |
Other Events, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2025 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (Com |
|
| April 4, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2025 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (Com |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-38022 CUSIP NUMBER NOTIFICATION OF LATE FILING 576810303 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐Tran |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (Co |
|
| March 11, 2025 |
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors Exhibit 99.1 Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors BEDMINSTER, N.J. (March 11, 2025) – Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the “Effective Date”). In addition, Matthew Wikler |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (Co |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| February 21, 2025 |
EXHIBIT 99.4 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13D, dated February 21, 2025 (the “Schedule 13D”), with respect to the common stock, par value $0.0001 of Matinas BioPharma Holdings, Inc. is, and any amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) u |
|
| February 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| February 21, 2025 |
EXHIBIT 99.4 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13D, dated February 21, 2025 (the “Schedule 13D”), with respect to the common stock, par value $0.0001 of Matinas BioPharma Holdings, Inc. is, and any amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) u |
|
| February 19, 2025 |
REPORTING PERSON TRANSACTIONS OF COMMON STOCK DURING THE PAST 60 DAYS EX-99.1 2 fp0092402-1ex991.htm EXHIBIT 1 REPORTING PERSON TRANSACTIONS OF COMMON STOCK DURING THE PAST 60 DAYS Reporting Person Effecting Transaction Date Type of Transaction Number of Shares Price Per Share How Transaction Effected 111 Equity Group 12/16/2024 Buy 2,697 0.54 Open Market 111 Equity Group 12/16/2024 Buy 24,030 0.54 Open Market 111 Equity Group 12/16/2024 Buy 35 0.55 Open Market 111 |
|
| February 13, 2025 |
Exhibit 3.1 MATINAS BIOPHARMA HOLDINGS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151(g) OF THE delaware GENERAL CORPORATION LAW The undersigned, Jerome D. Jabbour, does hereby certify that: 1. The undersigned is the Chief Executive Officer of Matinas Biopharma Holdings, Inc., a Delaware corporation (the “Corp |
|
| February 13, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 13, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 13, 2025, between Matinas Biopharma Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms an |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) |
|
| February 13, 2025 |
Exhibit 99.1 Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors BEDMINSTER, N.J. (February 13, 2025) – Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (the “Company”) today announced that the Company entered into a securities purchase agreement (the “Agreement”) with a certain group of investors (the “ |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2025 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) ( |
|
| February 7, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2025 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) ( |
|
| February 7, 2025 |
Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair Exhibit 99.1 Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair BEDMINSTER, N.J. (February 7, 2025) – Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of Evelyn D’An to its Board of Directors as an independent director and Chair of the Audit Committee, effective Wednesday, February 5, 2025. Ms. D’An is an experienced board di |
|
| January 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) ( |
|
| January 10, 2025 |
Matinas BioPharma Receives NYSE Noncompliance Notice Exhibit 99.1 Matinas BioPharma Receives NYSE Noncompliance Notice BEDMINSTER, N.J. (January 10, 2025) – Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that on January 6, 2025, it received a NYSE American LLC notice indicating that the Company has fallen below certain NYSE American continued listing standards because it failed to hold its annual meeting of stockholders for the fis |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2025 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (C |
|
| January 6, 2025 |
REPORTING PERSON TRANSACTIONS OF COMMON STOCK DURING THE PAST 60 DAYS EXHIBIT 2 REPORTING PERSON TRANSACTIONS OF COMMON STOCK DURING THE PAST 60 DAYS Reporting Person Effecting Transaction Date Type of Transaction Number of Shares Price Per Share How Transaction Effected 111 Equity Group 11/21/2024 Buy 10,000 0. |
|
| January 6, 2025 |
EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the common stock of Matinas Biopharma Holdings, Inc. |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2024 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARM |
|
| October 31, 2024 |
Exhibit 99.1 Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction BEDMINSTER, N.J. (October 31, 2024) – Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that negotiations under the previously disclosed non-binding term sheet regarding global rights to MAT2203, its oral formulation of amphotericin B, have been t |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) ( |
|
| October 25, 2024 |
MTNB / Matinas BioPharma Holdings, Inc. / HIGHBRIDGE CAPITAL MANAGEMENT LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Matinas BioPharma Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 576810303 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rul |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2024 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) ( |
|
| September 3, 2024 |
Exhibit 3.1 Certificate of Amendment Pursuant to Section 242 of the General Corporation Law of the State of Delaware, Matinas BioPharma Holdings, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: 1. The name of the Corporation is Matinas BioPharma Holdings, Inc. The Corporation was incorporated by the filing of i |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2024 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (C |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2024 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (C |
|
| August 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2024 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (C |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOL |
|
| August 14, 2024 |
Corporate Presentation, dated August 14, 2024 Exhibit 99.2 |
|
| August 14, 2024 |
Exhibit 99.1 Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update Signs non-binding term sheet granting global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections 31 patients have enrolled in the MAT2203 Compassionate/Expanded Use Access Program with 6 additional patients under evalua |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (C |
|
| May 9, 2024 |
Exhibit 4.6 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of our common stock and preferred stock as set forth in our certificate of incorporation and bylaws, each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K to which this Exhibit 4.6 is a part. This summar |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (Commi |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HO |
|
| May 9, 2024 |
Exhibit 99.1 Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update Recent $10 million financing expected to fund planned development programs and operations into the second quarter of 2025 Discussions to secure a partner to advance MAT2203 into the Phase 3 ORALTO trial remain on track Company’s strategy to expand its LNC platform into inflammation and oncolo |
|
| April 5, 2024 |
Matinas BioPharma Announces Registered Direct Offering of $10 Million Exhibit 99.1 Matinas BioPharma Announces Registered Direct Offering of $10 Million BEDMINSTER, N.J., April 3, 2024 (GLOBE NEWSWIRE) - Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (“Matinas BioPharma” or the “Company”), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, today announced i |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 2, 2024 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or Other Jurisdiction of Incorporation) (Com |
|
| April 5, 2024 |
Exhibit 4.1 Execution Version COMMON STOCK PURCHASE WARRANT Matinas BioPharma Holdings, Inc. Warrant Shares: Issue Date: April 5, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date th |
|
| April 5, 2024 |
Exhibit 1.1 Execution Version A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 April 2, 2024 Matinas BioPharma Holdings, Inc. 1545 Route 206 South Bedminster, NJ 07921 Attention: Jerome Jabbour, Chief Executive Officer Re: Placement Agency Agreement Dear Mr. Jabbour: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Allia |
|
| April 5, 2024 |
Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 2, 2024, between Matinas BioPharma Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject t |
|
| April 4, 2024 |
33,333,334 Shares of Common Stock Warrants to Purchase up to 33,333,334 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-272580 PROSPECTUS SUPPLEMENT (To Prospectus dated June 20, 2023) 33,333,334 Shares of Common Stock Warrants to Purchase up to 33,333,334 Shares of Common Stock We are offering (i) 33,333,334 shares of our common stock and (ii) warrants to purchase up to an aggregate of 33,333,334 shares of our common stock (the “Warrants”). Each share of comm |
|
| March 28, 2024 |
Corporate Presentation dated March 28, 2024 Exhibit 99.1 |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (Co |
|
| March 27, 2024 |
Exhibit 4.6 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of our common stock and preferred stock as set forth in our certificate of incorporation and bylaws, each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K to which this Exhibit 4.6 is a part. This summar |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS |
|
| March 27, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (Co |
|
| March 27, 2024 |
Exhibit 21.1 Subsidiaries of Matinas BioPharma Holdings, Inc. Name State of Incorporation Matinas BioPharma, Inc. Delaware Matinas BioPharma Nanotechnologies, Inc. Delaware |
|
| March 27, 2024 |
Exhibit 99.1 Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded Use Access Program demonstrates potential of MAT2203 in treating multiple severe invasive fungal infections, |
|
| March 27, 2024 |
Matinas BioPharma Holdings, Inc. Compensation Recovery Policy* Exhibit 97.1 MATINAS BIOPHARMA HOLDINGS, INC. COMPENSATION RECOVERY POLICY (Adopted and approved on November 30, 2023) 1. Purpose Matinas BioPharma Holdings, Inc. (collectively with its subsidiaries, the “Company”) is committed to promoting high standards of honest and ethical business conduct and compliance with applicable laws, rules and regulations. As part of this commitment, the Company has a |
|
| March 27, 2024 |
Matinas BioPharma Holdings Corp. Insider Trading Policy* Exhibit 19.1 MATINAS BIOPHARMA HOLDINGS, INC. STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND POLICY REGARDING SPECIAL TRADING PROCEDURES* Two copies of this Statement of Company Policy on Insider Trading and Policy Regarding Special Trading Procedures (collectively, this “Policy”) are being provided to you. You should read this Policy, address questions to Jerome D. Jabbour, the Chief Executiv |
|
| March 25, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (Co |
|
| March 25, 2024 |
Exhibit 99.1 Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel Results build on data from prior in vivo study of oral LNC-docetaxel showing reductions in t |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2024 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (Co |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2024 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (Co |
|
| March 22, 2024 |
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards Exhibit 99.1 Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards BEDMINSTER, N.J. (March 22, 2024) – Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, today announced that on March 21, 2024, the Company recei |
|
| March 22, 2024 |
Exhibit 99.1 Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response BEDMINSTER, N.J. (March 22, 2024) – Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform d |
|
| February 26, 2024 |
Exhibit 99.1 Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution A total of 19 patients with serious/life-threatening invasive fungal infections have been enrolled, including aspergillosis, mucormycosis, fusarium, candidiasis, cryptococcosis, and endemic mycoses such as coccidioi |
|
| February 26, 2024 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) |
|
| February 20, 2024 |
Exhibit 99.1 Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis ORALTO Phase 3 trial focused on desired initial target indication of early oral step-down treatment of invasive aspergillosis infections in adults who have limited or no treatment options Non-inferiority trial will |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) |
|
| January 9, 2024 |
Corporate Presentation dated January 9, 2024 Exhibit 99.1 |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (C |
|
| December 27, 2023 |
Exhibit 99.1 Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides In an acute colitis model, data show statistically significant knockdown of elevated levels of serum TNFα, reductions in tissue TNFα mRNA and improvement in disease activity scores In an acute psoriasis model, data show re |
|
| December 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2023 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) |
|
| December 21, 2023 |
Exhibit 99.1 Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA Written Preliminary Comments on the Phase 3 Registration Trial for MAT2203 Move Company Closer to Full Alignment with FDA Matinas to Meet with FDA Early in the First Quarter of 2024 to Finalize Phase 3 Study Design Partnership Discussions Remain Ongoing for MAT2203 BEDMINSTER, N |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) |
|
| November 20, 2023 |
Corporate Presentation dated November 20, 2023 Exhibit 99.1 |
|
| November 9, 2023 |
Exhibit 99.1 Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model Study results show reduction in tumor size comparable to IV docetaxel and no systemic toxicity BEDMINSTER, N.J. (November 7, 2023) – Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking th |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) ( |
|
| November 8, 2023 |
Exhibit 99.1 Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update FDA feedback on MAT2203 Phase 3 program supports a patient population in invasive aspergillosis with limited treatment options, acknowledges potential for LPAD pathway; composite superiority endpoint under evaluation to strengthen commercial opportunity without increasing study size Patient w |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARM |
|
| November 8, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) ( |
|
| November 2, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) ( |
|
| September 22, 2023 |
Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency Exhibit 99.1 Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency BEDMINSTER, N.J. (September 22, 2023) – Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its lipid nanocrystal (LNC) platform technology, today announced that it has |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) |
|
| September 20, 2023 |
Corporate Presentation dated September 20, 2023 Exhibit 99.1 |
|
| September 20, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) |
|
| September 19, 2023 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| September 8, 2023 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOL |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (Co |
|
| August 9, 2023 |
Exhibit 99.1 Matinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update FDA indicated that approval of MAT2203 as a first-line treatment for invasive aspergillosis will require an adequately powered study with an active control group and an all-cause mortality non-inferiority margin of 10% FDA provided alternative trial designs which include the highest-need pat |
|
| July 7, 2023 |
Up to $44,246,937 Common Stock Prospectus Supplement Filed Pursuant to Rule 424(b)(5) (To Prospectus dated June 20, 2023) Registration No. |
|
| June 16, 2023 |
Matinas BioPharma Holdings, Inc. 1545 Route 206 South, Suite 302 Bedminster, New Jersey 07921 Matinas BioPharma Holdings, Inc. 1545 Route 206 South, Suite 302 Bedminster, New Jersey 07921 June 16, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Matinas BioPharma Holdings, Inc. Registration Statement on Form S-3 (File No. 333-272580) Filed on June 9, 2023 Ladies and Gentlemen: In accordance with Ru |
|
| June 15, 2023 |
June 15, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 9, 2023 |
Form of Senior Debt Indenture and Matinas BioPharma Holdings, Inc. and the Trustee. Exhibit 4.5 MATINAS BIOPHARMA HOLDINGS, INC., as Issuer and ●, as Trustee INDENTURE Dated as of ● Senior Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between MATINAS BIOPHARMA HOLDINGS, INC. and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and (2) 5.08 310(a)(3) and (4) Inapplicable 310(b) 5 |
|
| June 9, 2023 |
As filed with the Securities and Exchange Commission on June 9, 2023 Registration No. |
|
| June 9, 2023 |
Consent of Lowenstein Sandler LLP (included in Exhibit 5.01). Exhibit 5.01 June 9, 2023 Matinas BioPharma Holdings, Inc. 1545 Route 206 South, Suite 302 Bedminster, New Jersey 07921 Re: Shelf Registration on Form S-3 Ladies and Gentlemen: This opinion is being furnished to you in connection with the Registration Statement on Form S-3 (the “Registration Statement”), including the base prospectus that is part of the Registration Statement (the “Prospectus”) fi |
|
| June 9, 2023 |
Form of Subordinated Debt Indenture and Matinas BioPharma Holdings, Inc. and the Trustee. EX-4.6 3 ex4-6.htm Exhibit 4.6 MATINAS BIOPHARMA HOLDINGS, INC., as Issuer and ●, as Trustee INDENTURE Dated as of ● Subordinated Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between MATINAS BIOPHARMA HOLDINGS, INC. and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and (2) 5.08 310(a)(3) and |
|
| June 9, 2023 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered (1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price (2) Amount of Registration Fee (3) Common Stock, $0. |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (Comm |
|
| May 10, 2023 |
Press Release, dated May 10, 2023 Exhibit 99.1 |
|
| May 10, 2023 |
Corporate Presentation, dated May 10, 2023 Exhibit 99.2 |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HO |
|
| April 18, 2023 |
Exhibit 99.1 Compassionate Use Patient Treated with Matinas BioPharma’s MAT2203 and Showing Complete Clinical Resolution of Rare R. mucilaginosa Fungal Infection Featured in Oral Presentation at ECCMID BEDMINSTER, N.J. (April 18, 2023) – Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LN |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2023 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (Co |
|
| March 31, 2023 |
As filed with the Securities and Exchange Commission on March 31, 2023 As filed with the Securities and Exchange Commission on March 31, 2023 Registration No. |
|
| March 31, 2023 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price per Share(2) Proposed Maximum Aggregate Offering Price(2) Amount of Registration Fee(2) Common Stock, $0. |
|
| March 15, 2023 |
Exhibit 10.17 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment (“Amendment”), dated as of March 3, 2023 (the “Amendment Date”), amends the Employment Agreement between MATINAS BIOPHARMA HOLDINGS, INC. (the “Company”) and JEROME D. JABBOUR (the “Executive”) dated as of March 22, 2018 (the “Agreement”). All capitalized terms not defined herein shall have the meanings set forth in the Agreement. R E |
|
| March 15, 2023 |
Exhibit 10.19 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment (“Amendment”), dated as of March 3, 2023 (the “Amendment Date”), amends the Employment Agreement between MATINAS BIOPHARMA HOLDINGS, INC. (the “Company”) and KEITH A. KUCINSKI, CPA (the “Executive”) dated December 31, 2018 and commencing as of January 2, 2019 (the “Agreement”). All capitalized terms not defined herein shall have the me |
|
| March 15, 2023 |
Exhibit 21.1 Subsidiaries of Matinas BioPharma Holdings, Inc. Name State of Incorporation Matinas BioPharma, Inc. Delaware Matinas BioPharma Nanotechnologies, Inc. Delaware |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS |
|
| March 15, 2023 |
Exhibit 99.1 Matinas BioPharma Reports 2022 Financial Results and Provides a Business Update Near-term data readouts from internal and collaborative programs expected to support advancement of the LNC platform for delivery of nucleic acids FDA feedback from MAT2203 Type B meeting expected to impact partnership discussions and facilitate potential non-dilutive BARDA and/or NIH funding Conference ca |
|
| March 15, 2023 |
Exhibit 10.18 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment (“Amendment”), dated as of March 3, 2023 (the “Amendment Date”), amends the Employment Agreement between MATINAS BIOPHARMA HOLDINGS, INC. (the “Company”) and THERESA MATKOVITS, Ph.D. (the “Executive”) dated September 25, 2018 and commencing as of October 15, 2018 (the “Agreement”). All capitalized terms not defined herein shall have th |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (Co |
|
| March 15, 2023 |
Exhibit 4.6 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of our common stock and preferred stock as set forth in our certificate of incorporation and bylaws, each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K to which this Exhibit 4.6 is a part. This summar |
|
| March 15, 2023 |
Exhibit 10.20 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment (“Amendment”), dated as of March 3, 2023 (the “Amendment Date”), amends the Employment Agreement between MATINAS BIOPHARMA HOLDINGS, INC. (the “Company”) and JAMES J. FERGUSON III, MD, FACC, FAHA (the “Executive”) dated February 22, 2019 and commencing as of February 25, 2019 (the “Agreement”). All capitalized terms not defined herein |
|
| January 30, 2023 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2023 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) ( |
|
| January 30, 2023 |
2023 Business Update and Strategic Outlook Presentation, January 30, 2023. Exhibit 99.2 |
|
| January 30, 2023 |
Exhibit 99.1 Matinas BioPharma Provides Business Update and 2023 Strategic Outlook 2022 Success Has Increased Confidence to Focus LNC Delivery Platform on the Future of Medicine - Delivering Genes Prioritization on Building External Partnerships and an Internal Pipeline Centered on Gene Therapies and Nucleic Acids Collaborations with BioNTech (mRNA Partner) and National Resilience (Nucleic Acid Pl |
|
| January 12, 2023 |
Exhibit 99.1 Matinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids BEDMINSTER, NJ, January 12, 2023 – Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LN |
|
| January 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2023 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) ( |
|
| December 29, 2022 |
Matinas BioPharma Holdings, Inc. 1545 Route 206, Suite 302 • Bedminster, NJ 07921 • USA Exhibit 99.1 December 29, 2022 Dear Matinas Stockholders, The end of any year is a good time to reflect upon our accomplishments as a company and to recognize some of the things that we can work to improve in the new year. There is little question that 2022 has been a challenging year for many, both from a market perspective and otherwise. We are cognizant of these challenges and remain intently f |
|
| December 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) |
|
| November 2, 2022 |
Exhibit 99.1 Matinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress EnACT Phase 2 study of MAT2203 in cryptococcal meningitis met its primary endpoint with 95% two-week patient survival in the Cohort 4 all-oral regimen Phase 3 pivotal trial of MAT2203 for treatment of cryptococcal meningitis to commence Q1 2023 The Infectious Diseases Society of America (IDSA |
|
| November 2, 2022 |
Corporate Presentation, November 2022 Exhibit 99.2 |
|
| November 2, 2022 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. THE OMISSIONS HAVE BEEN INDICATED BY “[***].” CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this “Consulting Agreement”) is made and entered into between Matinas BioPharma Holdings, Inc. (the “Company”), and Dr |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARM |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) ( |
|
| October 21, 2022 |
Exhibit 99.1 Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90% Two-week survival in Cohort 4 (all-oral regimen) was 95% in 40 patients receiving MAT2203 Mean Early Fungicidal Activity (EFA) of the rate of yeast clear |
|
| October 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) ( |
|
| October 21, 2022 |
Corporate Presentation, October 2022 Exhibit 99.2 |
|
| September 22, 2022 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only(as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statem |
|
| September 13, 2022 |
Corporate Presentation dated September 13, 2022 Exhibit 99.1 |
|
| September 13, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) |
|
| August 11, 2022 |
Exhibit 99.1 Matinas BioPharma Reports Second Quarter 2022 Financial Results and Highlights Recent Progress 75% of Patients Enrolled to Date in Cohort 4 of EnACT (MAT2203 in Cryptococcal Meningitis); Topline Data in Late Q3/Early Q4 2022 FDA Provides Flexibility and Clarity on Phase 3 Program and Single Pivotal Registration Trial for MAT2203 in Cryptococcal Meningitis; Trial Expected to Commence Q |
|
| August 11, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (C |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOL |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (Comm |
|
| May 12, 2022 |
Corporate Presentation, dated May 12, 2022 Exhibit 99.2 |
|
| May 12, 2022 |
Exhibit 99.1 Matinas BioPharma Reports First Quarter 2022 Financial Results and Operational Highlights ? Announced an exclusive research collaboration with BioNTech focused on the combination of mRNA and Matinas? proprietary LNC platform technology ? ? 50% of Patients Enrolled to Date in Cohort 4 of EnACT (MAT2203 in Cryptococcal Meningitis); Topline Data Expected Q3 2022 ? ? Feedback from Clinica |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HO |
|
| April 13, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (Co |
|
| April 13, 2022 |
Corporate Presentation dated April 13, 2022 Exhibit 99.1 |
|
| April 11, 2022 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (Co |
|
| April 11, 2022 |
Exhibit 99.1 BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines ? Exclusive collaboration combines BioNTech?s mRNA vaccine development expertise and Matinas? Lipid Nanocrystal (LNC) Delivery Platform Technology to advance novel formulations for mRNA vaccines, including a potential formulation for oral vaccines ? Ma |
|
| April 1, 2022 |
As filed with the Securities and Exchange Commission on April 1, 2022 As filed with the Securities and Exchange Commission on April 1, 2022 Registration No. |
|
| April 1, 2022 |
EX-FILING FEES 4 ex107.htm Exhibit 107 CALCULATION OF REGISTRATION FEE TABLES Form S-8 (Form Type) Matinas BioPharma Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Title of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price per Share(2) Proposed Maximum Aggregate Offering Price(2) Amount of |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS |
|
| March 8, 2022 |
Exhibit 99.1 Matinas BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights – Fifteen Patients Enrolled to Date in Cohort 4 of EnACT (all oral induction regimen); Topline Interim Data Expected Q3 2022 – – Potential Pathway to NDA Submission for MAT2203 with Confirmatory Data to Come from Cohort 5 of EnACT Trial – – Second in vivo Study of Oral LNC-remdesiv |
|
| March 8, 2022 |
Exhibit 10.15 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?), entered into on October 22, 2020 with the commencement of employment to begin as of December 1, 2020 (the ?Commencement Date?), is by and between MATINAS BIOPHARMA HOLDINGS, INC., a Delaware corporation (the ?Company?) and Dr. Hui Liu (the ?Executive?). W I T N E S S E T H: WHEREAS, the Company desires to employ the E |
|
| March 8, 2022 |
Exhibit 4.6 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of our common stock and preferred stock as set forth in our certificate of incorporation and bylaws, each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K to which this Exhibit 4.6 is a part. This summar |
|
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS |
|
| March 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (Com |
|
| March 8, 2022 |
Exhibit 21.1 Subsidiaries of Matinas BioPharma Holdings, Inc. Name State of Incorporation Matinas BioPharma, Inc. Delaware Matinas BioPharma Nanotechnologies, Inc. Delaware |
|
| March 8, 2022 |
Exhibit 10.16 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?), entered into on December 3, 2021 with the commencement of employment to begin as of December 6, 2021 (the ?Commencement Date?), is by and between MATINAS BIOPHARMA HOLDINGS, INC., a Delaware corporation (the ?Company?) and Thomas Hoover (the ?Executive?). W I T N E S S E T H: WHEREAS, the Company desires to employ the |
|
| February 14, 2022 |
MTNB / Matinas BioPharma Holdings Inc / Boxer Capital, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* MATINAS BIOPHARMA HOLDINGS, INC. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 576810105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| January 25, 2022 |
Exhibit 99.1 Matinas BioPharma Provides Business Update and 2022 Strategic Outlook ? End of Phase 2 Meeting with FDA Provides Pathway to NDA Submission for MAT2203 Following Confirmatory Data to be Generated in an Additional Cohort; Cohort 5 in Ongoing EnACT Trial ? ? Cohort 4 of EnACT (all oral induction regimen) Underway With Six Patients Enrolled and Topline Interim Data Expected Q3 2022 ? ? In |
|
| January 25, 2022 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) ( |
|
| December 16, 2021 |
Exhibit 99.1 Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Fourth and Final Cohort of Patients in the EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis ? DSMB evaluated both safety and efficacy data in recommending cohort progression ? ? Data from third patient cohort confirm antifungal activity above pre-defined threshold target for s |
|
| December 16, 2021 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2021 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) |
|
| December 6, 2021 |
Matinas BioPharma Appoints Thomas Hoover, M.B.A. as Chief Business Officer Exhibit 99.1 Matinas BioPharma Appoints Thomas Hoover, M.B.A. as Chief Business Officer BEDMINSTER, N.J., December 6, 2021 ? Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform delivery technology, today announced the app |
|
| December 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2021 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) ( |
|
| November 8, 2021 |
Exhibit 99.1 Matinas BioPharma Reports Third Quarter 2021 Financial Results and Operational Highlights ? Positive efficacy and safety data announced from first two cohorts of patients in ongoing EnACT study of MAT2203 (oral amphotericin B) for treatment of cryptococcal meningitis; DSMB unanimously recommended progression to second half of study ? ? Dosing initiated in Phase 1 study of potential fi |
|
| November 8, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) ( |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARM |
|
| November 1, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2021 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) ( |
|
| September 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2021 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) |
|
| September 20, 2021 |
Exhibit 99.1 Matinas BioPharma Announces Accomplished Biotechnology Executive and Drug Developer Kathryn Penkus Corzo as Nominee to the Board of Directors ? Ms. Corzo brings a 25+ year successful track record in biopharma, excelling in oncology drug development with Takeda, Sanofi Genzyme, and Eli Lilly ? BEDMINSTER, N.J., September 20, 2021 ? Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a |
|
| September 17, 2021 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only(as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statem |
|
| September 13, 2021 |
Exhibit 99.1 Matinas BioPharma Announces Positive Data in the Ongoing EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis, Exceeding the Prespecified Primary Endpoint Threshold ? Step-down therapy with MAT2203 achieved effective clearance of fungal organisms; Mean Early Fungicidal Activity (EFA) was 0.38, exceeding the prespecified primary endpoint threshold t |
|
| September 13, 2021 |
Slide Presentation, dated September 13, 2021. Exhibit 99.2 |
|
| September 13, 2021 |
Corporate Presentation, dated September 13, 2021. Exhibit 99.3 |
|
| September 13, 2021 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2021 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) |
|
| August 10, 2021 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 Matinas BioPharma Reports Second Quarter 2021 Financial Results and Operational Highlights – Enrollment complete in second cohort of EnACT study of MAT2203 (oral amphotericin B) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) review of safety and efficacy data from second cohort anticipated September 2021 – – Positive recent FDA feedback on MAT |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOL |
|
| August 10, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (C |
|
| May 10, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (Comm |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HO |
|
| May 10, 2021 |
Exhibit 99.1 Matinas BioPharma Reports First Quarter 2021 Financial Results and Operational Highlights ? Enrollment continues in second cohort of EnACT study of MAT2203 (oral amphotericin b) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) evaluation of safety and efficacy data from second cohort anticipated Q3 2021 ? ? MAT2501 (oral amikacin) advanced into preclinical toxicolog |
|
| March 29, 2021 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 Matinas BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights – Matinas to internally focus on its Lipid Nanocrystal (LNC) platform to improve the intracellular delivery of critical therapeutics – – Enrollment continues in second patient cohort of EnACT study of MAT2203 in cryptococcal meningitis; Data and Safety Monitori |
|
| March 29, 2021 |
EX-4.6 2 ex4-6.htm Exhibit 4.6 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of our common stock and preferred stock as set forth in our certificate of incorporation and bylaws, each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K to which this Exhibit 4.6 is |
|
| March 29, 2021 |
Exhibit 21.1 Subsidiaries of Matinas BioPharma Holdings, Inc. Name State of Incorporation Matinas BioPharma, Inc. Delaware Matinas BioPharma Nanotechnologies, Inc. Delaware |
|
| March 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDING |
|
| March 29, 2021 |
Exhibit 10.10 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. THE OMISSIONS HAVE BEEN INDICATED BY ?[***].? THERAPEUTIC DEVELOPMENT AWARD AGREEMENT November 17, 2020 Development Program: MAT2501 for the Treatment of NTM Infections in Cystic Fibrosis Patients Awardee: Matin |
|
| March 29, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2021 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (Co |
|
| February 26, 2021 |
As filed with the Securities and Exchange Commission on February 26, 2021 Registration No. |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* MATINAS BIOPHARMA HOLDINGS, INC. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 576810105 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Matinas BioPharma Holdings, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 576810105 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 1, 2021 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2021 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) ( |
|
| February 1, 2021 |
EX-99.1 6 ex99-1.htm Exhibit 99.1 Matinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISO™ Against Vascepa® – LYPDISO™ demonstrated a statistically significant 46% relative percent increase in EPA change from baseline over Vascepa ® – – LYPDISO™ demonstrated a 39% relative difference in response over Vascepa in TG reduction – – Primary endpoint of percent change from baseline |
|
| February 1, 2021 |
Slide Presentation, dated February 1, 2021. EX-99.2 11 ex99-2.htm Exhibit 99.2 |
|
| January 27, 2021 |
Submission of Matters to a Vote of Security Holders - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2021 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) ( |
|
| January 14, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2021 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) ( |
|
| January 14, 2021 |
Slide Presentation, dated January 14, 2021. Exhibit 99.1 |
|
| December 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2020 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction (Commission (IRS E |
|
| December 17, 2020 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy St |
|
| December 7, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2020 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38022 (Commission |
|
| December 7, 2020 |
Matinas BioPharma Files Preliminary Proxy for Special Meeting of Stockholders EX-99.2 3 nc10017450x3ex99-2.htm EXHIBIT 99.2 EXHIBIT 99.2 Matinas BioPharma Files Preliminary Proxy for Special Meeting of Stockholders – Special Meeting of Stockholders Scheduled for January 26, 2021 Seeking Authorization to Potentially Effectuate a Discretionary Reverse Stock Split Prior to January 26, 2022 – – Company’s Proposal to Stockholders Intended to Enhance Appeal of Common Stock to Ins |
|
| December 7, 2020 |
EXHIBIT 99.1 Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platform Delivery Technology BEDMINSTER, N.J. (December 7, 2020) – Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generat |
|
| December 7, 2020 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy St |
|
| December 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2020 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) ( |
|
| December 1, 2020 |
Exhibit 99.1 Matinas BioPharma Appoints Hui Liu, Ph.D., M.B.A. as Chief Technology Officer – Dr. Liu brings more than 20 years of expertise in pharmaceutical development, formulation, and CMC, with specific focus on lipid-based delivery of complex molecules – BEDMINSTER, N.J., December 1, 2020 – Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused |
|
| November 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2020 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) |
|
| November 25, 2020 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 Matinas BioPharma Awarded up to $3.75 Million from the Cystic Fibrosis Foundation to Support Development of Oral Amikacin (MAT2501) for the Treatment of NTM Infections in Cystic Fibrosis Patients BEDMINSTER, N.J., November 20, 2020 – Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation |
|
| November 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARM |
|
| November 6, 2020 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 Matinas BioPharma Reports Third Quarter 2020 Financial Results and Operational Highlights EnACT study of MAT2203 in cryptococcal meningitis received unanimous Data and Safety Monitoring Board (DSMB) recommendation to proceed into second patient cohort – ENHANCE-IT study of MAT9001 against Vascepa® fully enrolled with topline data anticipated Q1 2021; Phase 3 progr |
|
| November 6, 2020 |
Results of Operations and Financial Condition, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2020 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) ( |
|
| November 4, 2020 |
Submission of Matters to a Vote of Security Holders - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2020 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) ( |
|
| October 19, 2020 |
Exhibit 99.1 Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Second Cohort of Patients in the EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis – DSMB evaluated both safety and efficacy data in recommending cohort progression – – Enrollment in second cohort of patients expected to commence imminently with next DSMB evaluation anticipated |
|
| October 19, 2020 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2020 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) ( |
|
| October 1, 2020 |
DEF 14A 1 formdef14a.htm United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, For Use of the Commission Only(as permitted by Rule 14a-6 |
|
| September 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2020 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) |
|
| September 15, 2020 |
Matinas BioPharma Appoints Industry Veteran Natasha Giordano to Board of Directors Exhibit 99.1 Matinas BioPharma Appoints Industry Veteran Natasha Giordano to Board of Directors BEDMINSTER, N.J., September 14, 2020 – Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced the appointment of Natasha Giordano to its Board of Directors as an independent director and a member of the audit committee, effective Monday, September 14, 2020. Ms. Giordano brings over 25 years |
|
| September 15, 2020 |
Exhibit 99.2 Matinas BioPharma Announces Positive End of Phase 2 Meeting with the FDA for MAT9001 in Severe Hypertriglyceridemia (SHTG) - FDA Agreement to Move Directly into Phase 3 – - FDA to Require a Single Phase 3 Trial of 12 Weeks Duration to Support Efficacy for an NDA filing in SHTG - BEDMINSTER, N.J. (September 15, 2020) – Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stag |
|
| August 10, 2020 |
Up to $50,000,000 Common Stock 424B5 1 form424b5.htm PROSPECTUS Filed Pursuant to Rule 424(b)(5) Registration No. 333-239675 Up to $50,000,000 Common Stock This Sales Agreement prospectus and the accompanying base prospectus, which together we sometimes refer to as the prospectus, relates to the offer and sale, from time to time, of shares of our common stock having an aggregate gross sales price of up to $50,000,000, through B |
|
| August 10, 2020 |
Exhibit 99.1 Matinas BioPharma Reports Second Quarter 2020 Financial Results and Operational Highlights – ENHANCE-IT study of MAT9001 against Vascepa® expected to be fully enrolled in August 2020; topline data anticipated Q1 2021 – – EnACT study of MAT2203 in cryptococcal meningitis resumed enrollment; on track for potential cohort progression Q4 2020 – – Management to host conference call today, |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOL |
|
| August 10, 2020 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38022 46-3011414 (State or other jurisdiction of incorporation) (C |
|
| July 31, 2020 |
CORRESP 1 filename1.htm Matinas BioPharma Holdings, Inc. 1545 Route 206 South, Suite 302 Bedminster, New Jersey 07921 July 31, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Matinas BioPharma Holdings, Inc. Registration Statement on Form S-3 (File No. 333- 239675) Filed on July 2, 2020, as subsequently a |
|
| July 27, 2020 |
Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statement of Matinas BioPharma Holdings, Inc. and Subsidiaries (the “Company”) on Amendment No. 1 to Form S-3 to be filed on or about July 27, 2020 of our reports dated March 9, 2020, on our audits of the consolidated financial statements as of December 31, 2019 a |
|
| July 27, 2020 |
As filed with the Securities and Exchange Commission on July 27, 2020 Registration No. |
|
| July 27, 2020 |
July 27, 2020 VIA EDGAR TRANSMISSION Jason L. Drory, Attorney U.S. Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 RE: Matinas BioPharma Holdings, Inc. Registration Statement on Form S-3 Filed July 2, 2020 File No. 333-239675 Dear Mr. Drory: I am writing on behalf of Matinas BioPharma Holdings, Inc. (the “Company”), in response to the letter from the Staff |
|
| July 2, 2020 |
Consent of Lowenstein Sandler LLP (included in Exhibit 5.01). Exhibit 5.01 July 2, 2020 Matinas Biopharma Holdings, Inc. 1545 Route 206 South Suite 302 Bedminster, NJ 07921 Re: Shelf Registration on Form S-3 Ladies and Gentlemen: This opinion is being furnished to you in connection with the Registration Statement on Form S-3 (the “Registration Statement”), including the base prospectus that is part of the Registration Statement (the “Prospectus”) and the Sal |
|
| July 2, 2020 |
Form of Senior Debt Indenture and Matinas BioPharma Holdings, Inc. and the Trustee. Exhibit 4.5 MATINAS BIOPHARMA HOLDINGS, INC., as Issuer and ● , as Trustee INDENTURE Dated as of ● Senior Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between MATINAS BIOPHARMA HOLDINGS, INC. and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and (2) 5.08 310(a)(3) and (4) Inapplicable 310(b) |
|
| July 2, 2020 |
As filed with the Securities and Exchange Commission on July 2, 2020 Registration No. |
